Categories

Above the Fold

The Industry: Worth a look By John Irvine

Today contributor John Irvine reprises his role at FierceHealthcare with a guided tour of some of last week’s top healthcare stories. Go have a read and I’ll be back tomorrow  with more.

The FBI’s Upgrade that wasn’t

Five years ago the FBI announced it
would spend $170 million upgrading the paper filing system it had used to track cases and suspects since J.
Edgar Hoover’s day. The result was the Virtual
Case File
(VCF) a snazzy system developed by SAIC that looked as though it
was going to solve everybody’s problems. There was only one thing: the Virtual
Case File produced an error rate that was one of the worst experts had ever
seen. A year later the project was
dead. The Washington Post takes a look back at a debacle that may have helped
set the stage for the intelligence failures leading up to September 11 and
assesses SAIC’s responsibility for the project’s failure.

Annals of Generic Medicine

It is beginning to look as though
the Plavix debacle could cost Bristol–Myers
Squibb
CEO Peter Dolan his job, the Wall Street Journal reports. The company’s board pointedly chose not to
“reiterate previous statements of support” for Dolan last week. By allowing the
right to produce the blockbuster to
slip into the nefarious hands of another unscrupulous generic drug maker in a
lawless and faraway country (Canada), Dolan has cost his company dearly, the doubters say. How dearly? Dearly indeed. According to some
estimates, the loss of Plavix could BMS cost $3.8 billion, more than a third of
its revenues.

Fast times at the Cleveland Clinic

The Cleveland Clinic is “severing” its relationship with the
cardiologist who has led its technology transfer and commercialization division
since October 2005. The Cleveland Plain Dealer reported on Friday that an
internal review found that Dr Jay Yadav failed to disclose his continuing
involvement with Angioguard, a stent
company he sold to Johnson & Johnson before joining the hospital system. The Clinic has faced heat over its conflict of interest policies since a
Wall Street Journal story last year focusing on its relationships with outside
investors. According to the Plain
Dealer, Yadav continued to receive 1 % of Angioguard’s annual revenues even
after joining the healthcare system, as the inventor of Angioguard’s key
product.

Great moments in Cardiology

The Plain Dealer story on Yadav
includes mention of a classic snippet
of healthcare history most people don’t know about, describing how the owner of Fuddruckers, known for its giant
burgers and massive artery clogging portions of various fried delacies, helped finance research on the
first commercially successful stent in the 1980s. Critics argue that isn’t a coincidence that a maker of a popular
product known for its artery clogging ways helped fund a medical device used by
cardiologists to prop them open again. Hamburgers? Stents? By god, there really are conspiracies everywhere you
look.

Java for Java
In the past, it has often taken
weeks for reports of new cases of bird flu to make it to Jakarta from outlying
provinces. With Indonesia one of the most likely places for an influenza
pandemic to gain strength, that’s simply not good enough say critics. The Wall Street Journal reports that In October Indonesian authorities will test
a reporting system developed by D.C. based Voxiva that allows health
workers to send reports of suspected
H5N1 infections to Jakarta with their cell phones using text messaging. Those using Java enabled phones will be able
to input information directly into a database. Instead of relying on incident reports tallied by officials in Jakarta
on a monthly basis, supervisors will be able to call up a real time map showing
outbreaks. Very cool. And probably not a bad idea, either. 

Eye on Elyria

Unless you’re from certain parts of
northwestern central Ohio, you probably haven’t heard of the small town of Elyria, which sits a little bit to the
left of Cleveland on the map. Officials at the Centers for Medicare and
Medicaid Services apparently hadn’t either: at least until recently when
somebody pointed out that the rate for angioplasties in Elyria is about three
times the national average. A little
swift detective work by the New York Times traces the odd little statistical
anomaly to its source: the dedicated cardiologists at the North Ohio Heart
Center. Another example of doctors
guiding patients towards more lucrative procedures or simply an outlier? Critics
argue the former. Nay, say the cardiologists, we’re simply being aggressive.
Could we have another Redding Medical
Center
on our hands? wonder the fine folks at the NYT.

O Canada, Part II

Even Ronald Reagan, a reluctant
supporter of the AIDS cause, managed to make it. Critics are demanding to know why Canadian prime minister Stephen
Harper
, a critic of both needle exchange programs and gay rights, refused to show up for last week’s AIDS
Summit in Toronto, citing – of all things – a previous commitment to visit the
arctic circle. Instead of announcing his government’s new AIDS policy to
assembled scientists and activists in Toronto, Harper chose to be off
inspecting igloos.  Activists say Harper wants to dodge tough questions on his
decision not to extend
funding for a legal safe injection site in Vancouver that researchers say has
helped cut the incidence of new infections.

Sorry we can’t hire you, your genetic profile says you’re likely to be a heavy Myspace
user

A new Wall Street Journal/Harris
Poll
finds strong support for allowing health care providers, law enforcement
and personal use of genetic information gathered from DNA tests. Most of those
surveyed were a little less enthusiastic about allowing insurers or employers
access to the data. Only 14% say they approve of allowing insurers or employers
to have access to information about their genetic profiles. Oh, and ninety
three percent of Americans think the science of genetics is a “good thing.” One
percent find the concept “evil.”

We report you decide. You report we decide. Or something …

On Friday New York Governor George Pataki signed a bill that
extends a $10,000 tax credit
to New Yorkers who sign up to beome live organ
donors. Supporters say a similar
national law could help end the shortage of available organs. Is this a silly and ethically repugnant
solution to a pressing problem, like Arizona’s plan to encourage voter participation by making voters eligible for a $ 1 million
dollar prize or a clever market-based way to bribe the masses? We report. You
decide.

QUALITY/POLICY/HEALTH PLANS: Cranky, confused, aimless and spineless

And in the all talk and no action department…

Ian Morrison and Bob Leitman used to go around America calling employers’ attitude towards buying health care for their employees“cranky, confused, aimless and spineless”….that was in the early 1990s. It’s all different now, eh?  Well not quite. Deloitte survyed 71 big employers to find out how they were cracking the P4P whip on the system.

The joint Center/ERIC study looked at the views and attitudes of 71 major employers on value-based purchasing, also known as “pay for performance.” Some 10 percent of respondents are currently engaged in value-based reimbursement programs with health plans and/or provider networks, indicating a growing receptiveness to developing regional or pilot programs. However, 38 percent of surveyed employers are waiting for more concrete evidence that the concept can deliver a better return on investment.

Hmm.. so only 10% of big employers are doing anything about P4P. Employees working for employers with more than 1,000 employees represent about 13% of the private sector workforce (yup I scouted the Stat Abstract for that number). So less than 2% of employers are doing anything about P4P. In other words not enough for providers to take note of, so nothing will happen until Medicare makes its move.

PHARMA/POLITICS: Just when you thought it was safe to go back in the FDA toilet

Anti-Abortion Groups are opposing the FDA Nominee over the compromise on the OTC switch for for adults only for Plan B. Robert Steeves, who’s desperately trying to stay dry on what’s a fast receding sand bank for rational Republicans, writes to me to pick out one phrase from the story:

"Amid the political accusations, the FDA is contacting both the anti-abortion groups and their main opponent, Planned Parenthood, to hear their last-minute arguments over the fate of the drug, called Plan B. " 

Robert’s comment: This plebiscite is a first in the annals of NDA consideration and neither medical nor scientific, eh?

Well from this mob of faith-based crooks, what did he expect?  But even by my cynical standards this is going some.

But perhaps we’ve been looking at this the wrong way and instead there’s a new theme here. Forget those expensive clinical trials, let’s do all NDAs American Idol style!

Quiet today

I’m dealing with the not very nice condition of trigeminal neuralgia. I had it ten years ago and thankfully it went away after a few days. It seems to be getting better as the day goes on (possibly helped by the vast amount of ibuprofen I’m swallowing, and I’m trying to avoid breaking into my opiates), and hopefully it’ll soon go.

However, it’ll be quiet here today!

BLOGS: Quick blog round up

I’ m having a tough medical day myself so today I’m just sending you to two excellent bloggers—John Mack at the Pharma Marketing Blog on the new deconstruction of off-label marketing of Neurotin and its implications for consumer marketing, and MrHISTalk on a radical new (I think) interfacing company

Finally, here’s more proof if you need it that the health care system sucks, and the health care financing system especially for the poor sucks really badly— from the Commwealth Fund and Harris.

PHYSICIANS/POLICY: Concierge Medicine-Interview with Ed Goldman MDVIP

Does primary care have a future? And is that future a version of concierge medicine? It’s very early days, but yesterday I had a great conversation with Ed Goldman, CEO of MDVIP, a franchise concierge medicine company. He has some very interesting things to say about how concierge care may not just be for the worried wealthy.

The conversation is in this podcast
.
There’ll be a transcript available in a couple of days.

HOSPITALS: McKinsey wants to inspire lots of change; caveat emptor

McKinsey, an organization that prides itself on increasing the amount of consulting dollars it gets paid by improving the strategic direction of American business is making another foray into health care.

You may recall their last study on CDHPs was roundly criticized (see Tom Hillard for a good example including a hilarious and brutal smackdown of their research methodology in the last couple of paras), and this time they cleverly aren’t bothering with data—in fact they’re basically copying Porter and Teisberg. The piece, by Kurt Grote, Edward Levine and Paul Mango, is about hospitals and how they need to get into the 21st century.

And of course the idea is that hospitals need to change their business approach.  Well, given that I hadn’t noticed a rash of hospital closings and the the industry as a whole has been growing its revenues pretty successfully over the years, what exactly are the problems?

The rise of
employer-sponsored insurance in the 1930s and 1940s, and the emergence
of government-sponsored insurance in the 1960s all insulated hospitals
from the need to compete for patients. Today hospitals are “price
takers” for nearly 50 percent of their revenues, which is subject to
the political whims of the federal and state governments. Hospitals are
also required to see, evaluate, and treat virtually any patient who
shows up, solvent or not.
Furthermore, physicians were productive because hospitals put a great
deal of capital at their disposal. Yet these hospitals didn’t enforce
standardized and efficient approaches to the delivery of care. At many
hospitals today, doctors still bear only limited economic
responsibility for the care decisions they make. Little wonder that it
is often they who introduce expensive—and sometimes
excessive—nonreimbursable technologies or that hospitals not only
suffer from declining margins but are also performing less well than
other players in the health care value chain

The piece then has a pretty incomprehensible chart that compares the EBITDA (profit) of hospitals compared to drug companies and insurers. Surprisingly enough they make a whole lot less EBITDA than those businesses–although long time THCB readers will know we’ve been well down that path. And apparently their margins got worse and then better (from 25% in 1990 to 15% in 1995 to 10% in 2000 but back up to 15% in 2004).

McKinsey’s answer, basically filched from Porter/Teisberg, is for hospitals to specialize in particular service lines, stop being generalists and start trying to please the consumer who’ll be choosing among them. As a general mantra, this might be good for consultants to stick up on Powerpoint, but to be nice it’s massively oversimplified, and to be nasty it’s just plain wrong for most hospitals for the current and foreseeable medium-term future.

Their analysis ignores the fact that there are (at least) three broad categories of hospitals–inner city and rural  safety-net providers, big academic medical centers, and suburban community hospitals. Each of these has a completely different audience, completely different set of incentives, and more to McKinsey’s point, different profit margins.

Right up front they talk about the 50% of revenue that comes from the government–but for the first two categories, it’s more than that! And for everyone, as public programs grow, it’s going to be increasing.

Those hospitals relying on Medicare make most of their money but playing very careful attention to the DRG mix. The ones who play that game well and make most profit on Medicare outliers (like the for-profits McKinsey features in its metrics) don’t really want to change that by stopping their patients becoming those outliers, because if they get better at treating patients, they make less money. Brent James’ famous Intermountain story tells the truth, and until Medicare really changes the way it pays, you don’t want to be ahead of that curve. Intermountain may have spent more than 10 years leaving
money on the table, but those rich Mormons can afford it.

Meanwhile, for the mainstream community hospitals, as more and more services and patients leave the building, the imperative is not to change their business model, it’s to get their hands on that revenue that’s leaving with them. That’s why most big hospitals are now-co-investing with physicians in specialty hospitals et al. But while that’s a defensive battle to build better “hotels” for the star surgeons, it’s still about building better “hotels”–not junking the model of being the nicest possible host to the big time admitting surgeons.

The McKinsey/Porter/Teisberg theory is of course that if you get good at one service line, you’ll be attractive to consumers, and that they’ll choose you. There is more truth to this notion now than there was five years ago, but not much more. Doctors choose hospitals for their patients. That’s always been the case, other for those that get admitted via the ED, and that’s a function of location. That’s why hospitals suck up to surgeons. But even when consumers make choices, they’re not very active consumers beyond the deductible, and basically all hospital spending is beyond the deductible, and even in the cash non-hospital business (the stuff like genetic testing) most consumers take their doctor’s advice.

Which leads of course to who the other real consumer for the hospital is, and that’s the third party payer. First rule of dealing with payers is to figure out how to play the Medicare system well enough that you make it very profitable, but not too “well” that you get busted, a la Columbia/HCA, Tenet & St Barnabas.

Second rule is that you need to get bargaining strength against the health plans. No one can pretend that health plans really care in a global sense about having their providers cut costs and improve care delivery. They may say they care about it, but health plans add a chunk on the top of what they pay providers and stick that to their clients (usually employers) — who basically take it in a mealy mouthed way.

There is, though, a fight in any local market about where to draw the line on hospital pricing. But this fight is not about having providers from outside (or even within) the region swooping in to capture all a payer’s business with better pricing on certain service lines, and payers moving patients to these disease-specific treatment centers.  Well, it is about that in the McKinsey/Porter/Teisberg fantasy land, but in reality the fight is about setting global pricing for all the services a payer needs for its members in that region.

Look at the big fights going on now. In Denver there’s a dust-up between United HealthGroup and HealthOne and a similar one between United (again) and HCA in Florida. HealthOne is using a rather amusing tactic that–it says United should increase what it’s paying because it gave HealthOne a good report card. But let’s be real, this is about who can create enough market power so that the other side has to hand over a bigger slice of the pie if it wants services or patients delivered. Sutter showed this well when it beat up Blue Cross in California, and that lesson has been understood by provider systems across the nation as they lined up to form oligopolies.

If hospitals decide that they are going to improve care processes, and stop offering certain services, but offer the ones they are good at at a lower rate, insurers will say two things. First, thanks for the lower price, we’ll happily pay you less, and two, can you please organize coverage for the service lines you’re dropping as our patients in that metro area need it and don’t yet want to fly to Mumbai–they don’t even want to drive across town:

Aventura resident Jean Glick, who received a letter on Aug. 4, said she was furious. ‘If they claim to be a community hospital, this not serving your community,” she said. For Aventura residents insured by UnitedHealthcare, the next closest hospitals that accept their insurance are Parkway Regional in North Miami Beach and Mount Sinai in Miami Beach. <snip> Glick said she fears that not having a nearby hospital that accepts her health insurance could be expensive and even life threatening. ”I can’t afford to pay out of network,” she said.

The interviewed resident may not exactly understand the dynamics, but she doesn’t exactly sound ready for the brave new world. And let’s not underestimate the extent of the change McKinsey’s calling for. Here’s what they say about physicians:

For many physicians—particularly clinical specialists in the service lines where hospitals hope to differentiate themselves—the traditional arm’s-length and more recent competitive relationship must give way to some sort of formal employment or to gain-sharing schemes such as joint ownership of equipment or even whole facilities. Furthermore, performance criteria for physicians must shift. In a world in which transparent quality, service, and prices help patients choose places to seek treatment, metrics such as admissions volumes will become less relevant.

That looks like a license to drop a whole bunch of money hiring doctors and dealing with all the headaches that brings–not to mention dealing with the Stark laws. And all that just after the huge successes of hiring physicians in the 1990s! It would indeed be a brave CEO who stopped caring about the admission rates of his star surgeon. I can imagine the board meeting where he says that his hospital will have a smaller but more efficient service line that one day will grow to replace the others they’re dropping, and the gruff board member asks where the money to cross-subsidize the money-losing ED will come from.

It may be the case that in some far distant future patients can really be served (and moved around) on a national or international scale, and that the local monopoly/oligopoly model gets broken. But these things change very slowly. Delta airlines tried it about a decade back (flying employees around to centers of excellence)–have you noticed the huge impact on the system? Me neither.

Furthermore, almost none of the safety net hospitals, and few AMCs, can realistically take this course, as it destroys their mission of being all things to all comers. That matters not just because f their mission but because most of their money follows their mission. (For the safety-net via local taxes/Medicaid, and for the AMCs via Federal money for training residents and research).

I’m not saying that this is a good thing one way or the other. I’m in fact all in favor of changing incentives so that more efficient and better patient care is delivered, but I am saying that with the current and near-future market realities jumping on the McKinsey bandwagon is not a great idea for the vast majority of hospitals. But don’t worry—have McKinsey come in and change your strategy, and then in a few years they can come change it back!

CODA: It’s only fair to say that  a while back (in 2001)  one of the McKinsey authors Paul Mango wrote a prefectly sensible article about how hospitals could become more profitable by doing what they do now more efficiently, and understanding capacity optimization. And that five years later is pretty much still true.

assetto corsa mods